Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics
PRLD Price/Volume Stats
| Current price | $5.79 | 52-week high | $8.90 |
| Prev. close | $5.53 | 52-week low | $4.16 |
| Day low | $5.62 | Volume | 106,000 |
| Day high | $5.85 | Avg. volume | 85,829 |
| 50-day MA | $6.34 | Dividend yield | N/A |
| 200-day MA | $6.50 | Market Cap | 277.66M |
PRLD Stock Price Chart Interactive Chart >
Prelude Therapeutics Inc. (PRLD) Company Bio
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Latest PRLD News From Around the Web
Below are the latest news stories about PRELUDE THERAPEUTICS INC that investors may wish to consider to help them evaluate PRLD as an investment opportunity.
Prelude Therapeutics Announces Pricing of Public OfferingWILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to an aggregate of |
Prelude Therapeutics Announces Launch of Proposed Public OfferingWILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants are being offered by Prelude. In additi |
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateEight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress. “Our recent presentations at the 2023 AACR Annu |
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in MayWILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: H. C. Wainwright BioConnect Investor Conference at Nasdaq Kris Vaddi, Ph.D., Chief Executive Officer will participate in a fireside chat on Tuesday, May 2, at 1:30 p.m. ET. The live webcast is available here. The Compa |
Prelude Therapeutics to Present at American Association for Cancer Research 2023 ConferenceEight Abstracts Demonstrate Progress of Prelude’s Differentiated PipelineWILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. “Prelude's six preclinical and two clinical abstracts being presented at the AACR Annual |
PRLD Price Returns
| 1-mo | -6.01% |
| 3-mo | -0.17% |
| 6-mo | -18.34% |
| 1-year | 37.86% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -4.14% |
| 2022 | -51.49% |
| 2021 | -82.60% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...